Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions
Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions |
| [19-March-2026] |
Global data from over 12,000 consumers signals the future of modern aesthetics will be multimodal treatment plans and holistic, natural results Comprehensive data-based educational solutions to be presented at the Aesthetic and Anti-Aging Medicine World Congress 2026 (AMWC) in Monaco IRVINE, Calif., March 19, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and global leader in medical aesthetics, today announced new global consumer research highlighting how patient expectations in medical aesthetics are evolving, and will present the next evolution of its AA Signature™ framework, to address this changing treatment need, at the AMWC 2026 in Monaco. "Medical aesthetics is entering an exciting era, where patients are embracing a broader, more holistic perspective on their treatment journeys," remarked Mark Wilson, Senior Vice President, International, Allergan Aesthetics. "Our latest research offers compelling evidence of the shift in expectations – underscoring trends practitioners are already seeing in the clinic," Wilson continued. "Patients are not only increasingly willing to explore treatment combinations, but they are seeking greater clarity and truly bespoke plans to guide them towards authentic, natural-looking results over time." The findings are based on one of the largest global consumer studies exploring attitudes toward aesthetic treatments, surveying more than 12,000 beauty-involved consumers across nine countries.1 The research provides new insight into how patients are navigating an expanding range of aesthetic options and the growing role practitioners play in guiding treatment decisions. "At AMWC, our program provides a tangible demonstration of how Allergan Aesthetics has built a portfolio and education platform to help healthcare professionals deliver the results their patients' want. We continue to learn and evolve our proprietary multimodal approach, AA Signature™ through the introduction of elevated Signature Looks" Wilson continued. "Our proven portfolio is designed not only to perform individually, but to integrate seamlessly with one another and alongside other modalities. Through structured treatment frameworks, science and education, we're helping practitioners deliver personalised outcomes within holistic aesthetic treatment plans." At AMWC 2026, Allergan Aesthetics will launch the research findings in a new report Layered Beauty: The New Aesthetic Mindset. The report highlights that 62% find multiple aesthetic treatments appealing1, 59% are likely to adopt a structured multi-treatment approach1 and 78% would feel more satisfied with their aesthetic journey working to an agreed long-term plan with their practitioner.1 AA Signature™: One Year On AA Signature™ was developed in collaboration with experts as a portfolio-led framework to support personalised, multimodal treatment planning. One year on, AA Signature™ is evolving to include new elevated looks, expanded indications and enhanced product integration, reflecting changing patient expectations. Allergan Aesthetics' new research found that 74% intend to improve facial skin quality in the next 12 months,1 while 63% cite improving elasticity and addressing ageing as top aesthetic goals1(p33). Around 30% identify skin quality improvement as the starting point for a multi-treatment plan.1 Introducing AA Signature™ Skin360+ Designed around the way the skin behaves across layers and dimensions, AA Signature™ Skin 360+ was driven by real-world consumer needs and reinforces Allergan Aesthetics' commitment to continuously evolve how its portfolio works alone, and in combination with other modalities. At AMWC 2026 Allergan Aesthetics and globally recognised faculty will provide structured guidance to support sequential treatment planning, integrating injectable treatments with energy-based devices. AMI Programme at AMWC 2026 Allergan Aesthetics will bring the research insights and AA Signature™ evolution to life through two flagship symposia delivered by the Allergan Medical Institute (AMI).
Live injection sessions from Dr Mauricio De Maio will demonstrate combination approaches for chin and jawline correction alongside skin quality improvement, reinforcing the principle of small changes delivering meaningful impact. Medical Meetings A dedicated Global Medical Affairs Symposium, Innovation in Neurotoxins and Multimodal Approach: Transforming Aesthetic Practice Through Advanced Science, will take place on Friday 27 March in the Nijinski Auditorium, Grimaldi Forum. It will explore unmet needs in the neurotoxin arena, and the role of multimodal strategies beyond dynamic lines with expert panellists including Dr. Steven Dayan, Dr Terrane Keaney, Ada Regina Trindade de Almeida and Sylwia Lipko-Godlewska. Allergan Aesthetics will also present 21 scientific e-posters showcasing robust scientific innovation throughout its growing portfolio and demonstrating its leadership in advancing multimodal approaches to aesthetics. Science of Aging: The Future of Longevity Medicine in Aesthetics Global experts will explore how aging science has evolved throughout the years and discuss the importance of grounding the narrative around longevity medicine in foundational science and the translatability to the clinic setting.
Allergan Aesthetics Booth P3 Attendees can explore AA Signature™ approach, attend Meet the Expert sessions and engage with the Allergan Aesthetics portfolio at the company's booth (P3) throughout the congress. Through its integrated presence at AMWC 2026, Allergan Aesthetics continues to demonstrate its commitment to advancing multimodal aesthetic practice through innovation, education and science. References
Notes to editors: AA Signature About the research To better understand how today's culture is reshaping aesthetic decision-making, Allergan Aesthetics commissioned a large-scale global research study spanning nine countries (Canada, United States, United Kingdom, China, Brazil, France, Germany, Thailand and KSA) and more than 12,286 beauty-involved consumers. The study explored evolving attitudes, treatment behaviours and expectations around combination and multimodal approaches to aesthetics, revealing a clear shift away from isolated, single interventions towards the need for integrated, personalised treatment plans delivered over time. This research was undertaken to help Allergan Aesthetics better understand these changing behaviours and support the development of structured approaches to treatment such as AA Signature™, reflecting how patients now approach aesthetics. The research was carried out in November and December 2025. BOTOX® Cosmetic (onabotulinumtoxinA) Important Information Indications BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of: IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING WARNING: DISTANT SPREAD OF TOXIN EFFECT
CONTRAINDICATIONS WARNINGS AND PRECAUTIONS Spread of Toxin Effect No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur. Serious Adverse Reactions With Unapproved Use Hypersensitivity Reactions Cardiovascular System Increased Risk of Clinically Significant Effects With Preexisting Neuromuscular Disorders Dysphagia and Breathing Difficulties Preexisting Conditions at the Injection Site Dry Eye in Patients Treated With BOTOX®Cosmetic Human Albumin and Transmission of Viral Diseases ADVERSE REACTIONS The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%). The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%). The safety profile of BOTOX® Cosmetic treatment of platysma bands is consistent with the known safety profile of BOTOX® Cosmetic for other indications. DRUG INTERACTIONS The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic. USE IN SPECIFIC POPULATIONS Please see BOTOX® Cosmetic fullPrescribing Information, including Boxed Warning and Medication Guide. SKINVIVE by JUVÉDERM® Injectable Gel Important Information INDICATIONS IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: Not for patients with a history of anaphylaxis, presence of multiple severe allergies, or allergies to Gram-positive bacterial proteins or lidocaine in this product. WARNINGS: Do not inject into blood vessels as this may lead to embolization, occlusion of the vessels, ischemia, or infarction. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention should an intravascular injection occur. Treatment at specific sites should be deferred where there is an active inflammatory process or infection. PRECAUTIONS: Only healthcare professionals who have appropriate training, experience, and are knowledgeable of the anatomy at and around the injection site should use this product. As with all transcutaneous procedures, injections carry a risk of infection. The safety for use during pregnancy, breastfeeding, and in patients with known susceptibility to keloid formation, hypertrophic scarring, or pigmentation disorders has not been established. Use with caution in patients on immunosuppressive therapy. Patients taking medications that can prolong bleeding may experience increased bruising or bleeding at treatment sites. Patients may experience late onset AEs with use of injectable gel implants, including SKINVIVE by JUVÉDERM® ADVERSE EVENTS: The most commonly reported injection site responses included redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration, and itching. Most were mild, lasting 7 days or less. Please see Directions for Use or visit SKINVIVE.com for more information. SKINVIVE by JUVÉDERM® is available only by a licensed physician or properly licensed practitioner. The investigational products described above, TrenibotulinumtoxinE for the treatment of glabellar lines and SKINVIVE by JUVÉDERM® for the improvement of neck appearance, have not yet been shown to be safe and effective for their intended uses. About Allergan Aesthetics At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter)and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
SOURCE AbbVie | |||||
Company Codes: NYSE:ABBV |
View original content:
